Alex A. Adjei, MD, PhD, FACP

HER2 Mutations Present Unique Challenges in NSCLC

Targeted Therapies Expanding for MET Dysregulation in NSCLC

Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration

Guideline-Concordant Surgery, Adjuvant Therapy, and the Promise of Curative-Intent Lung Cancer Surgery: What Are We Up Against?

From the Editor: Looking Back on 2022

IASLC Announces New JTO CRR Editor-in-Chief

ILCN Names New Associate Editors

Increasing Evidence Demonstrates the Usefulness of ctDNA

In Brief for Feb. 8, 2023

CodeBreaK 200 Confirms Sotorasib’s Superiority Compared to Docetaxel, Investigator Says

Tobacco Smoking-Related Mutational Signatures: Is it Time to Move on From Patient-Reported History?